Boston Scientific posts positive stroke prevention data for Watchman

The company said it will seek an expanded indication for the left atrial appendage closure device after it met all safety and ...
KTBS 3

CHAMPION-AF study of the WATCHMAN FLX™ Left Atrial Appendage Closure Device as a first-line therapy for stroke risk reduction meets all primary and secondary safety and ...

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar efficacy compared to blood thinners in patients with non-valvular atrial fibrilla ...

Boston Scientific drops despite encouraging trial readouts

Boston Scientific Corporation BSX shares are down on Monday as the company faces pressure following a significant clinical ...
MedTech Intelligence

BSCI’s LAAC CHAMPION-AF study for WATCHMAN FLX meets primary and secondary safety and efficacy endpoints

Data highlights the WATCHMAN FLX device provided statistically superior protection from bleeding, demonstrated similar ...
MassDevice

Data supports Boston Scientific Watchman FLX in stroke reduction

Boston Scientific (NYSE:BSX) announced new findings from the CHAMPION-AF trial supporting its Watchman FLX system.